August 22, 2025 12:16 PM GMT CSPC Pharmaceutical Group | Asia Pacific 2025 Guidance Recalibrated after Soft 2Q; BD Targets and Sustainability Reiterated Key Takeaways Target 5% HoH growth in 2H25 and double-digit (%) growth from 202e:6: Mingfule is on track to hit Rmb1bn in sales in 2025. NBP soft capsule sales were hurt by tightened hospital budget control in 1H. CSPC plans to strengthen its out-of- pocket retail channel to sustain Rmb2bn sales after patent expiry. EGFR ADC updates ( Exhibit 1 ): Global Ph ...

Core Viewpoint - Crescent Capital BDC, Inc. reported its financial results for the quarter ended June 30, 2025, highlighting a net investment income of $0.46 per share and a net income of $0.41 per share, with a net asset value (NAV) per share of $19.55 [1][4]. Financial Performance - Net investment income for the second quarter was impacted by a one-time accelerated amortization of $0.02 per share related to deferred financing costs [1]. - Investment income increased to $43.0 million from $42.1 million in the previous quarter, with interest income rising to $40.1 million [6]. - Total net expenses for the quarter were $26.1 million, compared to $25.5 million in the previous quarter [7]. Dividend Declarations - The Board declared a regular cash dividend of $0.42 per share for the third quarter of 2025, payable on October 15, 2025 [2]. - A special dividend of $0.05 per share will be paid on September 15, 2025 [2]. Share Repurchase Program - The Board authorized a stock repurchase program to buy back up to $20.0 million of common stock in the open market [3]. Investment Portfolio - As of June 30, 2025, the company had investments in 187 portfolio companies with a fair value of $1,600.7 million [5]. - The portfolio comprised various asset types, with the largest being unitranche first lien loans at $1,043.6 million, representing 65.2% of the total investments [5]. Liquidity and Capital Resources - As of June 30, 2025, the company had $26.1 million in cash and cash equivalents and $227.2 million of undrawn capacity on its credit facilities [8]. - The weighted average cost of debt was 6.09%, and the debt to equity ratio stood at 1.23x [8].

Core Viewpoint - WhiteHorse Finance reported its financial results for Q2 2025, highlighting ongoing portfolio challenges but expressing confidence in the overall stability of its investments [2][3]. Financial Results - Total investment income for Q2 2025 was $18.838 million, a slight increase of 0.2% from $18.801 million in Q1 2025 [3]. - Total expenses, including excise tax, rose to $12.276 million, up 2.7% from $11.958 million in the previous quarter [3]. - Net investment income decreased to $6.562 million, down 4.1% from $6.843 million in Q1 2025, with a per-share income of $0.282 compared to $0.294 [3][18]. - The company declared a distribution of $0.385 per share for Q2 2025, consistent with the previous quarter [7][8]. Portfolio and Investment Activity - As of June 30, 2025, the fair value of the investment portfolio was $629.3 million, down 3.3% from $651.0 million as of March 31, 2025 [4]. - The portfolio consisted of 132 positions across 71 companies, with a weighted average effective yield of 11.9% on income-producing debt investments [4]. - During Q2 2025, the company invested $33.1 million in three new portfolio companies and added $5.9 million to existing companies [5]. Asset Management - The company transferred assets totaling $22.8 million to STRS JV in exchange for cash during the quarter [6]. - The net realized losses for the quarter were $22.045 million, while net unrealized appreciation was $17.733 million [3]. Shareholder Information - The distribution of $0.385 per share will be payable on October 3, 2025, to stockholders of record as of September 19, 2025 [7]. - The company has maintained distributions at or above $0.355 for 51 consecutive quarters since its IPO [8]. Management Commentary - The CEO noted that while earnings power remains below prior-year levels, progress is being made in resolving underperforming investments [2]. - The focus remains on credits with strong fundamentals, leveraging diversified sourcing capabilities and disciplined underwriting [2].

Financial Data and Key Metrics Changes - The company reported total revenues of $15.8 billion, a decrease of 2% both nominally and excluding foreign exchange impact [17] - Earnings per share were $2.13, with gross margin at 82.2%, an increase of 1.3 percentage points driven by favorable product mix [24][23] - The company expects full year revenue for 2025 to be between $64.3 billion and $65.3 billion, representing growth of 1% to 2% [26] Business Line Data and Key Metrics Changes - Oncology sales, particularly from Keytruda, increased by 9% to $8 billion, driven by robust demand for metastatic indications [18] - Sales of Gardasil decreased by 55% to $1.1 billion, primarily due to a decline in China [19] - The Animal Health business saw an 11% increase in sales, reflecting higher demand across all species [22] Market Data and Key Metrics Changes - Global growth excluding Gardasil in China was 7%, primarily driven by strength in oncology and animal health [17] - In the U.S., Vaxnuvance sales increased by 20%, benefiting from CDC stockpile activity [20] - The company anticipates a more significant headwind to growth in Japan for Gardasil in the second half of the year [28] Company Strategy and Development Direction - The company is focusing on a multi-year optimization initiative to redirect $3 billion of cost savings from lower growth areas to higher potential areas [25] - The acquisition of Verona Pharma is expected to enhance the cardiopulmonary program and reflects the company's commitment to transformative science [12] - The company aims to leverage its scientific expertise to deliver the next wave of innovations that can save and improve lives [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in returning to growth in 2025 and highlighted the strong clinical momentum and new product launches [9] - The company is entering a period of rapid transformation, with a diversified pipeline and over 20 new growth drivers [14] - Management acknowledged challenges in the Chinese market for Gardasil but remains focused on new product launches to drive growth [28] Other Important Information - The FDA approved Inflonsia for RSV prevention in infants, marking a significant milestone for the company [38] - The company is conducting over 80 phase three studies across various therapeutic areas, indicating strong clinical development activity [10] Q&A Session Summary Question: Context for outcomes in the Cadence trial - Management indicated that the most important signal for success is the PVR, with the six-minute walk also being important [52] Question: Market size for Winrevir and ex-U.S. strategy - Management noted that the patient population for Winrevir is underdiagnosed, and they expect growth in the ex-U.S. market as reimbursements come in [64] Question: $3 billion restructuring announcement - Management clarified that the $3 billion is a reallocation of resources from slower growth areas to fund faster-growing segments, with an expectation of overall growth in spending [70][72] Question: Gardasil demand dynamics and ACIP recommendations - Management expressed confidence in Gardasil's safety and efficacy but noted the high evidentiary standard set by the FDA for any changes in dosing recommendations [77] Question: Diligence in assets between Chinese and Western companies - Management emphasized a high standard for diligence regardless of the origin of the assets, highlighting the strategic advantage of the Verona acquisition [86] Question: Progress on Winrevir and patient adoption - Management reported steady growth in patient adds for Winrevir and increasing adoption among less severe patients [96]

I am hiring a BD lead for Helius, one of the fastest-growing startups in cryptoyou will be responsible for determining the future of Solana, how crypto is used in the world, and sourcing/closing high-stakes dealsnot for the faint of heart10% of salary as referral bonus https://t.co/FlTGK0uCQl ...

Core Viewpoint - Mirasol Resources Ltd. has signed an Option to Purchase Agreement with Eco Earth Elements SpA, granting Eco Earth exclusive rights to acquire the mineral rights of Mirasol's Nord East and Nord West Projects in Chile, which are strategically located near an advancing production project [1][2]. Agreement Terms - The total consideration for the acquisition of the Nord Projects is US$2,556,536, with US$2,044,986 allocated for Nord East and US$511,550 for Nord West, to be paid over four years [2][7]. - The payment schedule includes an initial payment of US$59,043 upon signing, followed by various payments totaling US$2,556,536 over four years [8]. Royalty Structure - Upon completion of payments, Eco Earth will earn a 100% interest in the Nord Projects, while Mirasol will retain a 2% Net Smelter Return (NSR) royalty on Nord East and a 1% NSR royalty on Nord West [4][7]. - Eco Earth has the option to purchase the first 1% of the 2% NSR royalty on Nord East for US$3 million and the remaining 1% for an additional US$6 million [4][7]. Project Overview - The Nord Projects cover 1,900 hectares and are located in Region II of Chile, adjacent to the Ciclón-Exploradora polymetallic-epithermal project, which is progressing towards production [5]. - Initial exploration indicates that the Nord East project may host significant mineralization, including polymetallic deposits of copper, zinc, lead, silver, and gold [6][9]. Company Background - Mirasol Resources Ltd. is an exploration company with over 20 years of experience in operating, permitting, and community relations in Chile and Argentina, currently self-funding exploration at its flagship Sobek Copper-Gold Project [10].

RT Jean-Paul Faraj (@Web3zy)Excited to share that I’ve joined @BanklessHQ to lead Business Development.After 5 years working full-time in crypto, I was clear on what I needed from my next role. My three non-negotiables were:1. Work with a team I genuinely respect2. Take on challenges that push me3. Surround myself with people who inspire growthBankless checks all three, and then some.They sit at the forefront of crypto media, producing content that educates and elevates the entire community. It’s an absolut ...

Regeneron Pharmaceuticals (REGN) FY Conference Summary Company Overview - **Company**: Regeneron Pharmaceuticals (REGN) - **Date of Conference**: June 09, 2025 - **Key Speakers**: Chris Feinmore (CFO), Ryan Crow (Head of IR and Strategic Analysis) Core Business and Strategy - **EYLEA Franchise Dynamics**: Focus on executing the strategy for EYLEA, Libtayo, and Dupixent, with a strong emphasis on internal R&D capabilities and pipeline development [4][5][7] - **Dupixent Performance**: Leading in all indications except for CSU, with a successful COPD launch underway [6][39] - **Libtayo Growth**: Recently became second in NBRxs, with optimistic data presented for adjuvant CSC [6][7] - **Pipeline Investments**: Approximately 45 assets in the pipeline, with key readouts expected in the second half of the year, including metastatic melanoma and myasthenia gravis data [7][8] Financial and Business Development - **Balance Sheet Flexibility**: Regeneron has a strong balance sheet, allowing for potential business development transactions to supplement the product portfolio [11][12] - **23andMe Acquisition**: Ongoing engagement in the auction process for 23andMe, viewed as a strategic opportunity for identity and validation [13][14] - **Share Buyback Strategy**: Average buyback of $1 billion over the past two quarters, with ongoing evaluation of capital allocation strategies [15][16] Regulatory and Manufacturing Updates - **FDA Applications**: Resubmission of the prefilled syringe application for EYLEA, with a decision expected in late August [24][25] - **Manufacturing Enhancements**: Building a fill-finish facility in New York and entering a partnership with Fuji Diosynth to double U.S. manufacturing capacity [22][23] Market Dynamics and Competitive Landscape - **Policy Environment**: Monitoring the fluid policy situation, including potential impacts from tariffs and drug policies [20][21] - **Co-Pay Assistance Programs**: Innovative matching program for co-pay assistance to support patient access to therapies [30][31] - **Competitive Response**: Actively monitoring competitors like Amgen and Roche, focusing on maintaining market share and accelerating EYLEA HD uptake [32][33] Pipeline Highlights - **Key Pipeline Data**: Anticipated data readouts for EYLEA HD, including enhancements for retinal vein occlusion and every four-week dosing [27][28] - **Dupixent Lifecycle Management**: Ongoing exploration of extended dosing intervals and adjacent type two inflammatory pathways [44][45] - **Melanoma and Lung Cancer Programs**: Confidence in LAG-three data for melanoma, with ongoing studies for lung cancer [56][59] Future Outlook - **Obesity Program**: Focus on fat loss rather than weight loss, with promising phase two data from the triplet program [50][51] - **Upcoming PDUFA Dates**: Lenvosteltenab on July 10 and odranextamab on July 30, with potential for earlier lines of therapy [67][70] - **Broad Pipeline**: Over 45 programs in development, with a focus on innovation across various therapeutic areas [71] Conclusion - Regeneron Pharmaceuticals is strategically positioned with a robust pipeline and strong financial flexibility, focusing on internal R&D and market competitiveness while navigating regulatory challenges and market dynamics. The company is optimistic about upcoming data readouts and potential new product launches.

Financial Data and Key Metrics Changes - Net sales for Q1 2025 were $18.9 million, a 17% decrease from $22.7 million in Q1 2024, primarily due to the largest customer transitioning to another supplier [12] - Gross profit for Q1 2025 was $3 million, consistent with Q1 2024, while gross margin increased to 16% from 14% in the same period last year [13] - Net loss for Q1 2025 was $1.5 million, an improvement from a net loss of $1.7 million in Q1 2024 [13] - Cash and cash equivalents decreased to $17.3 million from $21.6 million at the end of 2024, attributed to timing of payments and seasonal expenses [14] Business Line Data and Key Metrics Changes - The addition of a single-use bicarbonate cartridge technology to the product portfolio represents a growth opportunity in the dialysis products market [9] - The company continues to diversify its customer base, signing new contracts with leading hemodialysis providers [5] Market Data and Key Metrics Changes - Approximately 90% of revenue comes from U.S. dialysis providers, with only 10% generated internationally, and only one country is affected by recent U.S. tariff actions [8] - The company is actively pursuing business development opportunities to strengthen its position in the renal market and expand internationally [10] Company Strategy and Development Direction - The company aims to maintain a long-term arrangement with its largest customer, albeit at a smaller scale than previously [20] - Rockwell Medical is focused on expanding its customer base both domestically and internationally, particularly in Latin America and the West Coast of the U.S. [30][31] - The company is optimistic about the at-home dialysis market, which is expected to grow and provide higher margins [24] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges posed by the largest customer's transition but expressed confidence in the guidance provided for 2025 [21] - The second quarter is anticipated to be the low point for revenue, with expectations of improvement in subsequent quarters [22] Other Important Information - The company is monitoring the impact of a recent cyber attack in the industry but has not experienced direct implications on its systems [6] - The company has reiterated its projected guidance for 2025, with net sales expected between $65 million and $70 million [11] Q&A Session Summary Question: What are the scenarios arising from negotiations with the largest customer? - Management indicated that negotiations are ongoing to maintain some level of service, likely at a smaller scale than before [20] Question: What is the revenue cadence expected for the remainder of 2025? - Management stated it is difficult to predict but expressed confidence in the guidance provided, with Q2 likely being the low point [21][22] Question: What is the status of the at-home dialysis market? - The at-home market is progressing as expected, with increasing sales and higher margins anticipated [24] Question: What are the opportunities for international market expansion? - The company sees significant opportunities in Latin America and is exploring expansion into the West Coast of the U.S. [30][31] Question: How much revenue can be replaced from new customers? - Management believes there are enough opportunities among small independent dialysis providers to replace a significant portion of lost revenue [33] Question: Is the revenue guidance based on the current customer base? - Yes, the guidance is based on the current customer base, with potential upside from new customers [35]

Core Insights - TOMI Environmental Solutions, Inc. reported a 42% increase in revenue for Q1 2025 compared to the previous quarter, driven by strong demand for its product lines and recurring solution sales [2][3] - The company achieved a gross margin of 60.4%, slightly up from 60.2% in the prior year, and reduced its operating loss to $(754,000) from $(1,226,000) year-over-year [6] - Net loss decreased to $(256,000) or $(0.01) per share, compared to $(1,310,000) or $(0.07) per share in the same period last year [6] Financial Performance - Net sales for Q1 2025 were $1,577,000, up from $1,114,000 in Q1 2024, marking a significant year-over-year growth [6] - SteraMist product-based revenues increased to $1,000,000 from $743,000, reflecting a $257,000 rise due to heightened demand for various SteraMist solutions [6] - Service-based revenue also grew by 56%, reaching $577,000 compared to $371,000 in the prior year [6] Market Trends and Business Development - Domestic revenue surged by 80% to $1,192,000 from $662,000, attributed to increased demand for solutions and services [6] - The sales backlog as of March 31, 2025, was $1,225,000, an increase of $348,000 from December 31, 2024 [6] - A significant contract was secured for a SteraMist iHP Custom Engineered System at a university in Rhode Island, valued at approximately $450,000 [6] Strategic Partnerships and Expansion - TOMI announced the deployment of SteraMist iHP technology at NASA Johnson Space Center, indicating expansion into the aerospace sector [6] - An OEM partnership with Pharma Biotech System Components was established to enhance the SteraMist Integrated System [6] - The company is expanding into aquaculture with a new partner, Algafeed, further diversifying its market reach [7]